drugset / Trial / NCT04297280
TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization combined with anti-pd-1 antibody in patients with advanced hepatocellular carcinoma as first line therapy.
Timeline
- Start
- 2020-04-29
- Primary completion
- 2023-07-18
- Completion
- 2025-02-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Pirarubicin | Small molecule | — | — |